Search

Your search keyword '"Koshikawa, Ken"' showing total 25 results
Start Over Author "Koshikawa, Ken"
25 results on '"Koshikawa, Ken"'

4. Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial

Author

Kinouchi, Toru, primary, Terada, Jiro, additional, Sakao, Seiichiro, additional, Koshikawa, Ken, additional, Sasaki, Tsuyoshi, additional, Sugiyama, Atsuhiko, additional, Sato, Shun, additional, Sakuma, Noriko, additional, Abe, Mitsuhiro, additional, Shikano, Kohei, additional, Hayama, Nami, additional, Shiko, Yuki, additional, Ozawa, Yoshihito, additional, Ikeda, Shinobu, additional, Suzuki, Takuji, additional, and Tatsumi, Koichiro, additional

Published
2022
Full Text
View/download PDF

5. Development of a novel score model to predict hyperinflammation in COVID-19 as a forecast of optimal steroid administration timing

Author

Takeshita, Yuichiro, primary, Terada, Jiro, additional, Hirasawa, Yasutaka, additional, Kinoshita, Taku, additional, Tajima, Hiroshi, additional, Koshikawa, Ken, additional, Kinouchi, Toru, additional, Isaka, Yuri, additional, Shionoya, Yu, additional, Fujikawa, Atsushi, additional, Kato, Yasuyuki, additional, To, Yasuo, additional, Tada, Yuji, additional, and Tsushima, Kenji, additional

Published
2022
Full Text
View/download PDF

8. Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel

Author

Yoshioka,Keiichiro, Abe,Mitsuhiro, Shiko,Yuki, Koshikawa,Ken, Kawasaki,Yohei, Iwasawa,Shunichiro, Terada,Jiro, Tsushima,Kenji, Tatsumi,Koichiro, Suzuki,Takuji, Yoshioka,Keiichiro, Abe,Mitsuhiro, Shiko,Yuki, Koshikawa,Ken, Kawasaki,Yohei, Iwasawa,Shunichiro, Terada,Jiro, Tsushima,Kenji, Tatsumi,Koichiro, and Suzuki,Takuji

Abstract

Keiichiro Yoshioka,1 Mitsuhiro Abe,1 Yuki Shiko,2 Ken Koshikawa,1 Yohei Kawasaki,2 Shunichiro Iwasawa,1 Jiro Terada,1,3 Kenji Tsushima,3 Koichiro Tatsumi,1 Takuji Suzuki1 1Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan; 2Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan; 3Department of Pulmonary Medicine, International University of Health and Welfare, School of Medicine, Chiba, JapanCorrespondence: Mitsuhiro Abe, Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba, 260-8670, Japan, Tel +81 43 222 2576, Fax +81 43 226 2176, Email mthrsgnm@chiba-u.jpBackground/Aim: Nab-paclitaxel (Nab-PTX) has been widely used to treat several advanced cancers. Nab-PTX can cause drug-induced lung injury (DILI); however, its clinical and radiographic features have not been clarified. We aimed to assess the clinical characteristics of Nab-PTX-induced lung injury and identify its associated risk factors.Patients and Methods: We retrospectively investigated 304 patients who received Nab-PTX at Chiba University Hospital between November 2010 and November 2017. We obtained information regarding the clinical course, laboratory findings, and chest computed tomography findings from their medical records.Results: Forty-one patients (13%) developed DILI. Grade 1 lung injury occurred in 27 patients (8.8%), grade 2, 8 patients (2.6%); grade 3, 3 patients (0.9%); grade 4, 1 (0.3%); and grade 5, 2 (0.6%). Multivariate analysis revealed that age > 56 years (odds ratio [OR]: 3.0), pre-existing interstitial lung changes (OR: 3.2), and combined drugs with gemcitabine (OR: 2.7) were independent risk factors for DILI owing to Nab-PTX administration.Conclusion: Nab-PTX-induced lung injury is not rare; however, most cases are asymptomatic (grade 1). Older age, pre-existing interstitial lung changes, and combined drugs with gemcitabine could increase the incidence of Nab-PTX-i

Published
2022

9. Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial.

Author

Kinouchi, Toru, Terada, Jiro, Sakao, Seiichiro, Koshikawa, Ken, Sasaki, Tsuyoshi, Sugiyama, Atsuhiko, Sato, Shun, Sakuma, Noriko, Abe, Mitsuhiro, Shikano, Kohei, Hayama, Nami, Shiko, Yuki, Ozawa, Yoshihito, Ikeda, Shinobu, Suzuki, Takuji, and Tatsumi, Koichiro

Subjects
SLEEP apnea syndromes, JAPANESE people, SLEEP duration, RANDOMIZED controlled trials, ATOMOXETINE
Abstract

Background and Objective: The possibility of combination therapy with atomoxetine (ATO) and oxybutynin (OXY) has been suggested for obstructive sleep apnoea (OSA). However, the effectiveness of this treatment remains uninvestigated in Japanese OSA patients. Therefore, we performed a randomized, crossover, phase II, single‐centre prospective trial to examine the effects of ATO–OXY therapy in Japanese OSA patients. Methods: In total, 17 OSA patients participated in this study. The effects of one night of 80‐mg ATO plus 5‐mg OXY administration were compared with those of no medication administered before sleep. The primary and secondary outcomes comprised the apnoea–hypopnoea index (AHI) and nadir SpO2, SpO2 drop time and sleep architecture, respectively. The safety endpoints included drug side effects and adverse events. Results: The values of AHI, nadir SpO2, 3% oxygen desaturation index (ODI), 4% ODI, and SpO2 drop time of <90% did not significantly differ between patients receiving ATO–OXY administration and no medication. Sleep architecture exhibited a significant change: ATO–OXY increased sleep stage N1 (p < 0.0001) and decreased stage N2 (p = 0.03), rapid eye movement (p < 0.0001) and sleep efficiency (p = 0.02). However, the subanalysis demonstrated an obvious decrease in AHI in five responder patients. Total sleep time and basal sleep efficiency tended to be lower in the responders compared with nonresponders (p = 0.065). No patients experienced severe adverse events or side effects. Conclusion: Overall, ATO–OXY therapy does not reduce AHI in Japanese OSA patients, although AHI was decreased in a proportion of patients. Future studies for identifying treatment response group characteristics are warranted. This study is a prospective clinical trial of atomoxetine and oxybutynin combination therapy in Japanese patients with obstructive sleep apnoea (OSA). Unlike previous reports, no significant improvement in OSA severity was observed, although a significant change in sleep architecture was detected, suggesting a different reactivity in Japanese OSA patients. See relatedEditorial [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia

Author

Isaka, Yuri, primary, Hirasawa, Yasutaka, additional, Terada, Jiro, additional, Shionoya, Yu, additional, Takeshita, Yuichiro, additional, Kinouchi, Toru, additional, Koshikawa, Ken, additional, Tajima, Hiroshi, additional, Kinoshita, Taku, additional, Tada, Yuji, additional, Tatsumi, Koichiro, additional, and Tsushima, Kenji, additional

Published
2022
Full Text
View/download PDF

12. Elevated TAT in COVID-19 Patients with Normal D-Dimer as a Predictor of Severe Respiratory Failure: A Retrospective Analysis of 797 Patients

Author

Takeshita, Yuichiro, primary, Terada, Jiro, additional, Hirasawa, Yasutaka, additional, Kinoshita, Taku, additional, Tajima, Hiroshi, additional, Koshikawa, Ken, additional, Kinouchi, Toru, additional, Isaka, Yuri, additional, Shionoya, Yu, additional, Fujikawa, Atsushi, additional, Tada, Yuji, additional, Nakaseko, Chiaki, additional, and Tsushima, Kenji, additional

Published
2021
Full Text
View/download PDF

13. sj-pdf-3-pul-10.1177_2045894019873546 - Supplemental material for Characteristics of Japanese elderly patients with pulmonary arterial hypertension

Author

Takahashi, Yukiko, Yamamoto, Keiko, Tanabe, Nobuhiro, Suda, Rika, Koshikawa, Ken, Ikubo, Yumiko, Suzuki, Eiko, Shoji, Hiroki, Naito, Akira, Kasai, Hajime, Rintaro Nishimura, Sanada, Takayuki Jujo, Sugiura, Toshihiko, Shigeta, Ayako, Sakao, Seiichiro, and Tatsumi, Koichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, Cardiology
Abstract

Supplemental material, sj-pdf-3-pul-10.1177_2045894019873546 for Characteristics of Japanese elderly patients with pulmonary arterial hypertension by Yukiko Takahashi, Keiko Yamamoto, Nobuhiro Tanabe, Rika Suda, Ken Koshikawa, Yumiko Ikubo, Eiko Suzuki, Hiroki Shoji, Akira Naito, Hajime Kasai, Rintaro Nishimura, Takayuki Jujo Sanada, Toshihiko Sugiura, Ayako Shigeta, Seiichiro Sakao and Koichiro Tatsumi in Pulmonary Circulation

Published
2020
Full Text
View/download PDF

14. sj-pdf-2-pul-10.1177_2045894019873546 - Supplemental material for Characteristics of Japanese elderly patients with pulmonary arterial hypertension

Author

Takahashi, Yukiko, Yamamoto, Keiko, Tanabe, Nobuhiro, Suda, Rika, Koshikawa, Ken, Ikubo, Yumiko, Suzuki, Eiko, Shoji, Hiroki, Naito, Akira, Kasai, Hajime, Rintaro Nishimura, Sanada, Takayuki Jujo, Sugiura, Toshihiko, Shigeta, Ayako, Sakao, Seiichiro, and Tatsumi, Koichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, Cardiology
Abstract

Supplemental material, sj-pdf-2-pul-10.1177_2045894019873546 for Characteristics of Japanese elderly patients with pulmonary arterial hypertension by Yukiko Takahashi, Keiko Yamamoto, Nobuhiro Tanabe, Rika Suda, Ken Koshikawa, Yumiko Ikubo, Eiko Suzuki, Hiroki Shoji, Akira Naito, Hajime Kasai, Rintaro Nishimura, Takayuki Jujo Sanada, Toshihiko Sugiura, Ayako Shigeta, Seiichiro Sakao and Koichiro Tatsumi in Pulmonary Circulation

Published
2020
Full Text
View/download PDF

15. sj-pdf-1-pul-10.1177_2045894019873546 - Supplemental material for Characteristics of Japanese elderly patients with pulmonary arterial hypertension

Author

Takahashi, Yukiko, Yamamoto, Keiko, Tanabe, Nobuhiro, Suda, Rika, Koshikawa, Ken, Ikubo, Yumiko, Suzuki, Eiko, Shoji, Hiroki, Naito, Akira, Kasai, Hajime, Rintaro Nishimura, Sanada, Takayuki Jujo, Sugiura, Toshihiko, Shigeta, Ayako, Sakao, Seiichiro, and Tatsumi, Koichiro

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, Cardiology
Abstract

Supplemental material, sj-pdf-1-pul-10.1177_2045894019873546 for Characteristics of Japanese elderly patients with pulmonary arterial hypertension by Yukiko Takahashi, Keiko Yamamoto, Nobuhiro Tanabe, Rika Suda, Ken Koshikawa, Yumiko Ikubo, Eiko Suzuki, Hiroki Shoji, Akira Naito, Hajime Kasai, Rintaro Nishimura, Takayuki Jujo Sanada, Toshihiko Sugiura, Ayako Shigeta, Seiichiro Sakao and Koichiro Tatsumi in Pulmonary Circulation

Published
2020
Full Text
View/download PDF

16. Characteristics of Japanese elderly patients with pulmonary arterial hypertension

Author

Takahashi, Yukiko, primary, Yamamoto, Keiko, additional, Tanabe, Nobuhiro, additional, Suda, Rika, additional, Koshikawa, Ken, additional, Ikubo, Yumiko, additional, Suzuki, Eiko, additional, Shoji, Hiroki, additional, Naito, Akira, additional, Kasai, Hajime, additional, Nishimura, Rintaro, additional, Sanada, Takayuki Jujo, additional, Sugiura, Toshihiko, additional, Shigeta, Ayako, additional, Sakao, Seiichiro, additional, and Tatsumi, Koichiro, additional

Published
2020
Full Text
View/download PDF

17. Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis

Author

Koshikawa, Ken, primary, Terada, Jiro, additional, Abe, Mitsuhiro, additional, Iwasawa, Shunichiro, additional, Sakayori, Masashi, additional, Yoshioka, Keiichiro, additional, Hirasawa, Yasutaka, additional, Kasai, Hajime, additional, Kawasaki, Yohei, additional, Tsushima, Kenji, additional, and Tatsumi, Koichiro, additional

Published
2020
Full Text
View/download PDF

18. Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea

Author

Katsumata, Yusuke, primary, Terada, Jiro, additional, Matsumura, Takuma, additional, Koshikawa, Ken, additional, Sakao, Seiichiro, additional, Tomiyoshi, Go, additional, Shinmen, Natsuko, additional, Nakamura, Rika, additional, Kuroda, Hideyuki, additional, Nagashima, Kengo, additional, Kobayashi, Yoshio, additional, Kobayashi, Eiichi, additional, Iwadate, Yasuo, additional, Zhang, Xiao-Meng, additional, Hiwasa, Takaki, additional, and Tatsumi, Koichiro, additional

Published
2020
Full Text
View/download PDF

19. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience

Author

Matsumura,Takuma, Terada,Jiro, Yoshimura,Chikara, Koshikawa,Ken, Kinoshita,Taku, Yahaba,Misuzu, Nagashima,Kengo, Sakao,Seiichiro, Tatsumi,Koichiro, Matsumura,Takuma, Terada,Jiro, Yoshimura,Chikara, Koshikawa,Ken, Kinoshita,Taku, Yahaba,Misuzu, Nagashima,Kengo, Sakao,Seiichiro, and Tatsumi,Koichiro

Abstract

Takuma Matsumura,1 Jiro Terada,1 Chikara Yoshimura,2 Ken Koshikawa,1 Taku Kinoshita,1 Misuzu Yahaba,1 Kengo Nagashima,3 Seiichiro Sakao,1 Koichiro Tatsumi1 1Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan; 2Department of Respiratory and Sleep Medicine, Fukuoka University School of Medicine, Fukuoka, Japan; 3Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tokyo, Japan Purpose: Although patients with suspected obstructive sleep apnea (OSA) might suffer difficulty in falling asleep during overnight polysomnography (PSG), standard hypnotics to obtain sleep during PSG have not been established. The aim of this study was to investigate the safety and efficacy of a new hypnotic agent, suvorexant, a dual orexin receptor antagonist, for insomnia in suspected OSA patients during in-laboratory PSG.Patients and methods: An observational study was conducted during PSG for 149 patients with suspected OSA who had no insomnia at home. Patients with difficulty in falling asleep during PSG were optionally permitted to take single-use suvorexant. Patients with residual severe insomnia (>1 hour) after taking suvorexant were permitted to take an add-on use zolpidem. Clinical data and sleep questionnaire results were analyzed between a no insomnia group (without hypnotics) and an insomnia group (treated with suvorexant).Results: Among 84 patients who experienced insomnia during PSG and required hypnotics (the insomnia group; treated with suvorexant), 44 (52.4%) achieved sufficient subjective sleep with single-use of suvorexant, while the other 40 (47.6%) required suvorexant plus zolpidem. An apnea hypopnea index (AHI) of ≥5 was observed in 144 out of 149 patients with predominantly obstructive respiratory events. Among those patients, 70.8% in the no insomnia group and 63.1% in the insomnia group had severe OSA. Regarding both subjective sleep time and morning mood, significant differences

Published
2019

24. Elevated TAT in COVID-19 Patients with Normal D-Dimer as a Predictor of Severe Respiratory Failure: A Retrospective Analysis of 797 Patients.

Author

Takeshita, Yuichiro, Terada, Jiro, Hirasawa, Yasutaka, Kinoshita, Taku, Tajima, Hiroshi, Koshikawa, Ken, Kinouchi, Toru, Isaka, Yuri, Shionoya, Yu, Fujikawa, Atsushi, Tada, Yuji, Nakaseko, Chiaki, and Tsushima, Kenji

Subjects
ETIOLOGY of diseases, RESPIRATORY insufficiency, COVID-19, FIBRIN fragment D, DISSEMINATED intravascular coagulation, BODY mass index
Abstract

Although previous studies have revealed that elevated D-dimer in the early stage of coronavirus 2019 (COVID-19) indicates pulmonary intravascular coagulation, the state of coagulation/fibrinolysis disorder with normal D-dimer is unknown. The study aimed to investigate how coagulation/fibrinolysis markers affect severe respiratory failure in the early stage of COVID-19. Among 1043 patients with COVID-19, 797 patients were included in our single-center retrospective study. These 797 patients were divided into two groups, the normal D-dimer and elevated D-dimer groups and analyzed for each group. A logistic regression model was fitted for age, sex, body mass index (BMI) ≥ 30 kg/m2, fibrinogen ≥ 617 mg/dL, thrombin-antithrombin complex (TAT) ≥ 4.0 ng/mL, and plasmin-alpha2-plasmin inhibitor-complex (PIC) > 0.8 µg/mL. A multivariate analysis of the normal D-dimer group demonstrated that being male and TAT ≥ 4.0 ng/mL significantly affected severe respiratory failure. In a multivariate analysis of the elevated D-dimer group, BMI ≥ 30 kg/m2 and fibrinogen ≥ 617 mg/dL significantly affected severe respiratory failure. The elevated PIC did not affect severe respiratory failure in any group. Our study demonstrated that hypercoagulation due to SARS-CoV-2 infection may occur even during a normal D-dimer level, causing severe respiratory failure in COVID-19. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results